Literature DB >> 28689368

Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.

Federico Pessina1, Pierina Navarria2, Luca Cozzi2,3, Anna Maria Ascolese2, Matteo Simonelli4, Armando Santoro4, Elena Clerici2, Marco Rossi5, Marta Scorsetti2,3, Lorenzo Bello5.   

Abstract

The extent of surgical resection (EOR) has been recorded as conditioning outcome in glioblastoma multiforme (GBM) patients but no significant improvements were recorded in survival. The study aimed to evaluate the impact of EOR on survival, investigating the role of fluid-attenuated inversion recovery (FLAIR) abnormalities removal. 282 newly diagnosed GBM patients were treated with surgery followed by concurrent and adjuvant chemo-radiotherapy. The EOR was defined as: SUPr, in case of resection amounting to 100% of enhanced and FLAIR areas; gross total (GTR) in case of resection between 90 and 100% of enhanced areas with variable amount of FLAIR abnormalities; sub-total (STR), between 10 and 89%; biopsy (B) <10%. FLAIR-RTV was dichotomized in percentage values to identify the best separation threshold for progression free survival (PFS) and overall survival (OS). SUPr was obtained in 21 patients (7.4%), GTR in 60 (21.3%), STR in 143 (50.7%) and biopsy only in 58 (20.6%). The median, 1, 2-year PFS were 10.4 ± 0.4 months, 39.0 ± 3.0, and 17.0 ± 2.0%; the median, 1, 2-year OS were 14.5 ± 0.5 months, 63.3 ± 3.0, and 23.1 ± 3.1%. EOR was significantly influencing survival (p < 0.001). The median, 1, 2-year OS were 28.6 ± 5.2 months, 90.0 ± 6.0, 71.0 ± 10.0% for patients underwent SUPr vs. 16.2 ± 1.2 months, 81.0 ± 5.0, 24.0 ± 6.0% for GTR. The FLAIR removal threshold conditioning survival was 45%. Minor complications were recorded in 14 (5%) patients and major in 8 (2.8%). surgical resection beyond contrast-enhancing boundaries could represent a promising strategy to improve outcome in GBM patients. The identification of a FLAIR-RTV threshold can be useful in clinical practice and it was recorded as factor influencing survival.

Entities:  

Keywords:  Eloquent areas; Extent of surgical resection; FLAIR infiltration; Glioblastoma; Maximal resection; Neurophysiological monitoring

Mesh:

Substances:

Year:  2017        PMID: 28689368     DOI: 10.1007/s11060-017-2559-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

Review 1.  Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors.

Authors:  R Sawaya; M Hammoud; D Schoppa; K R Hess; S Z Wu; W M Shi; D M Wildrick
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

2.  Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways.

Authors:  Lorenzo Bello; Marco Riva; Enrica Fava; Valentina Ferpozzi; Antonella Castellano; Fabio Raneri; Federico Pessina; Alberto Bizzi; Andrea Falini; Gabriella Cerri
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

3.  Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.

Authors:  Mark W McDonald; Hui-Kuo G Shu; Walter J Curran; Ian R Crocker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-14       Impact factor: 7.038

4.  An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.

Authors:  Mark E Oppenlander; Andrew B Wolf; Laura A Snyder; Robert Bina; Jeffrey R Wilson; Stephen W Coons; Lynn S Ashby; David Brachman; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai
Journal:  J Neurosurg       Date:  2014-01-31       Impact factor: 5.115

5.  Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.

Authors:  Michael C Dobelbower; Omer L Burnett Iii; Robert A Nordal; Louis B Nabors; James M Markert; Mark D Hyatt; John B Fiveash
Journal:  J Med Imaging Radiat Oncol       Date:  2011-02       Impact factor: 1.735

6.  Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article.

Authors:  Yordanka N Yordanova; Sylvie Moritz-Gasser; Hugues Duffau
Journal:  J Neurosurg       Date:  2011-05-06       Impact factor: 5.115

7.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

8.  The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma.

Authors:  Maryam Rahman; Joseph Abbatematteo; Edward K De Leo; Paul S Kubilis; Sasha Vaziri; Frank Bova; Elias Sayour; Duane Mitchell; Alfredo Quinones-Hinojosa
Journal:  J Neurosurg       Date:  2016-09-30       Impact factor: 5.115

9.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.

Authors:  Justin S Smith; Edward F Chang; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Soonmee Cha; Tarik Tihan; Scott Vandenberg; Michael W McDermott; Mitchel S Berger
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

10.  A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle.

Authors:  K R Swanson; R C Rostomily; E C Alvord
Journal:  Br J Cancer       Date:  2007-12-04       Impact factor: 7.640

View more
  32 in total

Review 1.  Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.

Authors:  A Lasocki; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-04       Impact factor: 3.825

Review 2.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

3.  Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection.

Authors:  Matthias Schneider; Anna-Laura Potthoff; Vera C Keil; Ági Güresir; Johannes Weller; Valeri Borger; Motaz Hamed; Andreas Waha; Hartmut Vatter; Erdem Güresir; Ulrich Herrlinger; Patrick Schuss
Journal:  J Neurooncol       Date:  2019-09-04       Impact factor: 4.130

4.  A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma.

Authors:  Christina Jackson; John Choi; Adham M Khalafallah; Carrie Price; Chetan Bettegowda; Michael Lim; Gary Gallia; Jon Weingart; Henry Brem; Debraj Mukherjee
Journal:  J Neurooncol       Date:  2020-06-19       Impact factor: 4.130

5.  Supratotal resection in glioma: a systematic review.

Authors:  Charles N de Leeuw; Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

Review 6.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

7.  Postoperative outcomes following glioblastoma resection using a robot-assisted digital surgical exoscope: a case series.

Authors:  Rebecca B Baron; Nikita Lakomkin; Alexander J Schupper; Dominic Nistal; Kambiz Nael; Gabrielle Price; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2020-06-09       Impact factor: 4.130

8.  Glioblastoma Survival Outcomes at a Tertiary Hospital in Appalachia: Factors Impacting the Survival of Patients Following Implementation of the Stupp Protocol.

Authors:  Ogaga Urhie; Ryan Turner; Brandon Lucke-Wold; Walid Radwan; Janice Ahn; Kymberly Gyure; Sanjay Bhatia
Journal:  World Neurosurg       Date:  2018-04-06       Impact factor: 2.104

9.  Intraoperative B-Mode Ultrasound Guided Surgery and the Extent of Glioblastoma Resection: A Randomized Controlled Trial.

Authors:  Fatih Incekara; Marion Smits; Linda Dirven; Eelke M Bos; Rutger K Balvers; Iain K Haitsma; Joost W Schouten; Arnaud J P E Vincent
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

10.  Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study.

Authors:  Federico Pessina; Pierina Navarria; Elena Clerici; Luisa Bellu; Andrea Franzini; Davide Milani; Matteo Simonelli; Pasquale Persico; Letterio S Politi; Alessandra Casarotti; Bethania Fernandes; Simone Olei; Martina Sollini; Arturo Chiti; Marta Scorsetti
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.